DAWN vs. SPRY

Last updated Apr 1, 2026

Compare and contrast key facts about Day One Biopharmaceuticals, Inc. (DAWN) and Silverback Therapeutics Inc (SPRY).

Performance

DAWN vs. SPRY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Day One Biopharmaceuticals, Inc. (DAWN) and Silverback Therapeutics Inc (SPRY). The values are adjusted to include any dividend payments, if applicable.

DAWN vs. SPRY - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
DAWN Day One Biopharmaceuticals, Inc.	130.04%	-26.44%	-13.22%	-32.16%	27.72%	-34.92%
SPRY Silverback Therapeutics Inc	-31.07%	10.43%	92.52%	-35.76%	28.08%	-75.20%

Fundamentals

EPS DAWN : -$1.47 SPRY : -$1.74
PS Ratio DAWN : 16.56 SPRY : 9.39
Total Revenue (TTM) DAWN : $133.67M SPRY : $84.28M
Gross Profit (TTM) DAWN : $119.56M SPRY : $45.85M
EBITDA (TTM) DAWN : -$141.73M SPRY : -$175.98M

Returns By Period

In the year-to-date period, DAWN achieves a 130.04% return, which is significantly higher than SPRY's -31.07% return.

DAWN

• 1D: 0.09%
• 1M: 102.26%
• YTD: 130.04%
• 6M: 204.11%
• 1Y: 170.37%
• 3Y*: 17.05%
• 5Y*: —
• 10Y*: —

SPRY

• 1D: 2.75%
• 1M: -13.47%
• YTD: -31.07%
• 6M: -20.10%
• 1Y: -36.17%
• 3Y*: 7.25%
• 5Y*: -28.93%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

DAWN vs. SPRY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DAWN

DAWN Risk / Return Rank: 92
DAWN Sharpe Ratio Rank: 87
DAWN Sortino Ratio Rank: 94
DAWN Omega Ratio Rank: 91
DAWN Calmar Ratio Rank: 95
DAWN Martin Ratio Rank: 92

SPRY

SPRY Risk / Return Rank: 21
SPRY Sharpe Ratio Rank: 17
SPRY Sortino Ratio Rank: 19
SPRY Omega Ratio Rank: 20
SPRY Calmar Ratio Rank: 23
SPRY Martin Ratio Rank: 24

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DAWN vs. SPRY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Day One Biopharmaceuticals, Inc. (DAWN) and Silverback Therapeutics Inc (SPRY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	DAWN	SPRY	Difference
Sharpe ratio Return per unit of total volatility	1.68	-0.54	+2.22
Sortino ratio Return per unit of downside risk	3.42	-0.50	+3.92
Omega ratio Gain probability vs. loss probability	1.42	0.94	+0.48
Calmar ratio Return relative to maximum drawdown	6.08	-0.56	+6.65
Martin ratio Return relative to average drawdown	12.95	-0.97	+13.93
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

DAWN vs. SPRY - Sharpe Ratio Comparison

The current DAWN Sharpe Ratio is 1.68, which is higher than the SPRY Sharpe Ratio of -0.54. The chart below compares the historical Sharpe Ratios of DAWN and SPRY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	DAWN	SPRY	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.68	-0.54	+2.22
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.36	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.04	-0.24	+0.20

Correlation

The correlation between DAWN and SPRY is 0.27, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

DAWN vs. SPRY - Dividend Comparison

Neither DAWN nor SPRY has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

DAWN vs. SPRY - Drawdown Comparison

The maximum DAWN drawdown since its inception was -79.51%, smaller than the maximum SPRY drawdown of -95.20%. Use the drawdown chart below to compare losses from any high point for DAWN and SPRY.

Drawdown Indicators

	DAWN	SPRY	Difference
Max Drawdown Largest peak-to-trough decline	-79.51%	-95.20%	+15.69%
Max Drawdown (1Y) Largest decline over 1 year	-27.23%	-63.32%	+36.09%
Max Drawdown (5Y) Largest decline over 5 years	—	-93.45%	—
Current Drawdown Current decline from peak	-23.21%	-86.71%	+63.50%
Average Drawdown Average peak-to-trough decline	-47.87%	-77.98%	+30.11%
Ulcer Index Depth and duration of drawdowns from previous peaks	12.79%	36.73%	-23.94%

Volatility

DAWN vs. SPRY - Volatility Comparison

Day One Biopharmaceuticals, Inc. (DAWN) has a higher volatility of 55.60% compared to Silverback Therapeutics Inc (SPRY) at 17.65%. This indicates that DAWN's price experiences larger fluctuations and is considered to be riskier than SPRY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	DAWN	SPRY	Difference
Volatility (1M) Calculated over the trailing 1-month period	55.60%	17.65%	+37.95%
Volatility (6M) Calculated over the trailing 6-month period	80.38%	51.95%	+28.43%
Volatility (1Y) Calculated over the trailing 1-year period	101.86%	67.04%	+34.82%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	93.26%	80.53%	+12.73%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	93.26%	81.43%	+11.83%

Financials